

SHAREHOLDER INFORMATION SESSIONS AND WEBCAST

- Shareholder information sessions to be held in Sydney and New York
- Sydney Session November 13, 2014 at 10.10am AEDST, with the session to commence directly after the AGM. The presentation and Q+A session will be webcast for all shareholders.
- New York Session November 19, 2014 at 10am EST

Sydney 31 October, 2014: Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it will be holding information sessions for shareholders in Sydney and New York in November, 2014.

The sessions will include a short presentation from Benitec's CEO and Managing Director, Dr Peter French, followed by questions, and the opportunity for shareholders to meet with members of Benitec's Board and Management.

Shareholders unable to attend in person are invited to register for a live webcast and Q+A.

Sydney Session

Date and time: November 13, 2014 at 10.10am AEDT (directly following the AGM, which will commence at 9.30am AEDT at the same venue)

Venue: Grant Thornton Australia
Level 17, 383 Kent Street
Sydney NSW 2000

Shareholder Information Session webcast

Date and time: November 13, 2014 at 10.10am AEDT (directly following the AGM)
The Sydney information session will be webcast for the benefit of those investors unable to attend the event in person.

Access: To listen to the presentation and participate in the Q+A session, please register to attend the webcast, by copying and pasting the following link into your web browser, then following the prompts:
<http://www.brrmedia.com/event/129135?popup=tue>

New York Session

Date and time: November 19, 2014 at 10.00am EST

Venue: Doubletree by Hilton Metropolitan, New York
569 Lexington Ave,
New York, NY 10022



An archived copy of the webcast will be lodged with the ASX after the Sydney information session.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT; OTC: BTEBY) which has developed a patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licencees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS and retinitis pigmentosa. For more information visit www.benitec.com.